title: Commentary: Evaluating oversight of human drugs and medical devices.
abstract: This article seeks to provide insights into appropriate FDA oversight of nanotechnology. This commentary identifies limitations in the methodology employed and concludes that the analysis would be stronger with a more in-depth institutional dimension based on administrative law and political science research.
authors.affiliation: Medical Technology Leadership Forum, USA.
authors.forename: Susan Bartlett
authors.initials: SB
authors.lastname: Foote
mesh_terms: D003257:Consumer Product Safety; D004335:Drug and Narcotic Control; D006801:Humans; D050997:Nanomedicine / Q000331:legislation & jurisprudence*; D011050:Policy Making; D014481:United States; D014486:United States Food and Drug Administration